SINOBIOMED INC.

Hier noch eine heutige News!

Press Release Source: Sinobiomed Inc.

Sinobiomed Subsidiary Commences Production of Recombinant Acidic Fibroblast Growth Factor (aFGF)

Wednesday July 18, 9:00 am ET

SHANGHAI, CHINA--(MARKET WIRE)--Jul 18, 2007 -- Sinobiomed Inc. (the \"Company\") (OTC BB:SOBM.OB - News) is pleased to announce that Shanghai Wanxing Bio-pharmaceuticals Co., Ltd.\'s (\"Shanghai Wanxing\" - an 82% owned subsidiary of the Company) has commenced production of recombinant acidic Fibroblast Growth Factor (aFGF). Shanghai Wanxing\'s production facility for aFGF recently received its GMP (Good Manufacturing Practice) Certification by the Chinese SFDA. As approved by the Chinese SFDA, aFGF is a drug for the treatment of ulceration including deep burns (more than 2nd degree burns) and chronic ulcers caused by burn wounds, diabetes, vascular diseases and bed sores. aFGF is expected to enter the market in August 2007 with a production volume of approximately 20 million boxes per year and will retail for US $15.5/box. At present 200 distributors are negotiating with the company to distribute the product.

In der Pressemitteilung steht dass das MEdi aGFG innerhalb eines Jahres ca 20 Mio PAckungen verkaufen werden zum Preis von 15.5 USD pro Packung.

20 Mio * 15.5 usd = 310 Mio

310 Mio / Anzahl Aktien 115 Mio= 0.27 USD Gewinn pro Aktie

KGV = 2.80 USD / 0.27 = 10.37 USD

Stimmt meine Rechnung und Überlegungen? wenn ja ist die Aktie ja noch einiges unterbewertet :shock:

Was meint Ihr?

Hallo Zusammen hier ein kleiner Update!

In einem solchen Markt !! unglaublich! Ist jemand dabei?

Sinobiomed's Malaria Vaccine Granted European Patent

2007-07-25 09:00 (New York)

Sinobiomed's Malaria Vaccine Granted European Patent

New Patent Provides Protection in up to 37 Countries in Europe

SHANGHAI, CHINA -- (MARKET WIRE) -- 07/25/07 -- Sinobiomed Inc.

("Sinobiomed", "the Company") (OTCBB: SOBM) is pleased to announce

that the European Patent Office (EPO) has granted a patent for the

malaria vaccine PfCP2.9 to which Sinobiomed has exclusive rights to

develop, manufacture and sell through its 82 percent owned

subsidiary, Shanghai Wanxing Bio-pharmaceuticals Co., Ltd. ("Shanghai

Wanxing"). The EPO provides patent protection in up to 37 European

countries.

EPO patent number 1357128, dated July 4, 2007, has been assigned to

the Second Military Medical University (SMMU) of Shanghai China for

the preparation and dosage of plasmodium fusion antigen invented by

Dr. Weiqing Pan. Dr. Pan, an advisor to Sinobiomed and an

internationally recognized researcher, heads the Department of

Parasitology at SMMU and serves on China's national committee to

combat parasitic diseases. The U.S. Patent and Trademark Office

granted SMMU a patent for the plasmodium fusion antigen in September

2006.

"The granting of the European patent further strengthens Sinobiomed's

ability to proceed with the vaccine's development with full

confidence in its potential for commercial development for the global

market," said Company President and CEO Banjun Yang. "The potential

benefits to humanity as well as to Sinobiomed shareholders are

significant."

The invention provides a fusion protein comprising the Plasmodium

merozoite surface protein-1 (MSP1) and the Plasmodium apical membrane

antigen 1 (AMA-1), the encoding DNA sequence, the vector containing

the sequence, the host cell containing the vector and the genetic

engineering method for preparing the fusion protein and the usage for

producing anti-malarial vaccine. The patent holder was granted the

right to exclude others from making, using, offering for sale, or

selling the invention throughout Europe with 20 years protection term

from the date on which the earliest application was filed (February

1, 2002).

On Mar 22, 2001, Second Military Medical University and Shanghai

Wanxing signed a collaboration and license agreement that gives

Shanghai Wanxing the exclusive right to exploit such technology,

including the right to manufacture and sell the malaria vaccine it

develops. Sinobiomed is developing and testing the plasmodium fusion

antigen as a blood-stage malaria vaccine with the support of the

World Health Organization (WHO) and the Malaria Vaccine Initiative

(MVI) of the Program for the Appropriate Technology in Health (PATH).

Sinobiomed's malaria candidate vaccine (PfCP2.9) targets the world's

most deadly malaria parasite (Plasmodium falciparum) at its most

destructive stage-its rapid replication in human red blood cells. In

the now completed Phase I Clinical Trial, PfCP2.9 showed greater

immunogenicity and fewer adverse reactions. The Chinese State Food

and Drug Administration (SFDA), which has a drug approval process

similar to that of the U.S. FDA, has approved PfCP2.9 for a Phase II

Clinical Trial to be conducted in China's Yunnan Province and in

Southeast Asia.